PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-304.29%
Negative EBIT growth while Biotechnology median is -0.22%. Seth Klarman would check if external or internal factors caused the decline.
27.06%
Positive operating income growth while Biotechnology is negative. Peter Lynch would spot a big relative advantage here.
-304.05%
Negative net income growth while Biotechnology median is -1.19%. Seth Klarman would investigate factors dragging net income down.
-302.06%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-288.66%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.11%
Share change of 0.11% while Biotechnology median is zero. Walter Schloss would see if the modest difference matters long-term.
3.68%
Diluted share change of 3.68% while Biotechnology median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
56.08%
OCF growth of 56.08% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
56.11%
FCF growth of 56.11% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18524.76%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-17391.51%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-1778.39%
Negative 3Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-42866.91%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
-15208.07%
Negative 5Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-5247.61%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
4590.00%
Equity/share CAGR of 4590.00% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
1682.71%
5Y equity/share CAGR of 1682.71% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
1405.22%
3Y equity/share CAGR of 1405.22% while Biotechnology median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.82%
Asset growth of 70.82% while Biotechnology median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
247.25%
BV/share growth of 247.25% while Biotechnology is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-50.51%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-53.09%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
3.56%
SG&A growth far above Biotechnology median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.